Skip to main content
    C

    Caris Life Sciences, Inc. Common Stock (CAI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $21.00
    -2.04 (-8.85%)

    Market Cap: $6.61B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Caris Life Sciences, Inc. Common Stock (CAI) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Caris Life Sciences, Inc. Common Stock (CAI) trades at 5.7x sales and 9.3x book value. Its forward P/E is 31.6x.

    Current Multiples

    Its free cash flow yield is 0.5%.

    MultipleValue
    P/E (trailing)N/A
    Forward P/E31.6x
    Price to sales5.7x
    Price to book9.3x
    Price to FCF206.2x
    PEGN/A
    FCF yield0.5%

    As of Nov 17, 2026

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About CAI

    What is CAI's forward P/E ratio?

    Caris Life Sciences, Inc. Common Stock has a forward P/E ratio of 31.6x.

    Is CAI stock overvalued?

    GNG's valuation label for CAI is Undervalued.

    What is CAI's price to sales ratio?

    Caris Life Sciences, Inc. Common Stock has a price to sales ratio of 5.7x.